Berthel Fisher & Co Financial Services’s Franklin Genomic Advancements ETF HELX Stock Holding History
Bought
Maintained
Sold
Other funds holding HELX
Berthel Fisher & Co Financial Services's HELX Position: Q3 2026 in Review
Berthel Fisher & Co Financial Services held its Franklin Genomic Advancements ETF (HELX) position steady in Q3 2026 at 401 shares worth $17.9K. The position accounts for ﹤0.01% of the portfolio, ranked #875.
Berthel Fisher & Co Financial Services first reported a position in HELX in Q3 2024 and has held it in 9 quarters since. The position peaked at $29.2K in Q3 2024. 11 funds tracked by Wall St. Rank hold HELX as of Q3 2026.
- Berthel Fisher & Co Financial Services held 401 shares of Franklin Genomic Advancements ETF worth $17.9K as of Q3 2026.
- Berthel Fisher & Co Financial Services left its Franklin Genomic Advancements ETF share count unchanged in Q3 2026.
- Franklin Genomic Advancements ETF made up ﹤0.01% of Berthel Fisher & Co Financial Services's portfolio in Q3 2026, its #875 holding.
- Berthel Fisher & Co Financial Services first reported a position in Franklin Genomic Advancements ETF in Q3 2024 and has held it in 9 quarters since.
- Berthel Fisher & Co Financial Services's Franklin Genomic Advancements ETF position peaked at $29.2K in Q3 2024.
- 11 funds tracked by Wall St. Rank held Franklin Genomic Advancements ETF as of Q3 2026.
Based on Berthel Fisher & Co Financial Services's 13F filing for Q3 2026, filed 13 Nov 2026.